Uganda: Experts Warn Lenacapavir Is an HIV Prevention Tool, Not a Vaccine
Health experts in Kampala have issued a public clarification regarding the newly introduced HIV prevention injection Lenacapavir, warning that the long-acting drug should not be mistaken for a vaccine. While describing the treatment as a significant development in the response to HIV, specialists stressed that those who have already received their first dose should continue to consider combination prevention strategies.
A Twice-Yearly Prevention Option
Lenacapavir has drawn considerable attention within the global health community as one of the latest long-acting injectable options for HIV pre-exposure prophylaxis, known as PrEP. Unlike daily oral PrEP regimens, the drug is administered as an injection only twice a year, a feature that has been widely welcomed as a potential breakthrough for individuals who face challenges adhering to daily medication. Health advocates have pointed to its longer dosing interval as a way to reduce stigma and improve consistency of use among at-risk populations.
Clarifying the Science
Despite enthusiasm surrounding the drug, experts convened in Kampala have emphasised that Lenacapavir does not function as an HIV vaccine. A vaccine, by definition, trains the immune system to recognise and fight a virus over the long term, often providing lasting protection without ongoing medication. Lenacapavir, by contrast, is an antiretroviral agent that must be administered on a continuing basis to maintain its protective effect. Without regular follow-up injections, its preventive benefit diminishes, leaving users vulnerable to infection.
The Case for Combination Prevention
Public health authorities have long advocated for a layered approach to HIV prevention, combining biomedical tools with behavioural and structural interventions. Experts reviewing the rollout of Lenacapavir in Uganda have echoed that message, encouraging users of the injection to also consider additional measures such as condom use, regular testing, and access to other preventive options where appropriate. The goal, they noted, is to ensure that confidence in a single tool does not lead to the abandonment of other protective behaviours.
Looking Ahead
Uganda continues to record progress in its broader HIV response, with expanded access to testing and treatment credited for declining transmission rates in recent years. The introduction of long-acting prevention options is expected to complement those gains, provided they are deployed alongside sustained public education. The experts’ warning underscores a recurring theme in HIV programming: no single intervention, however promising, can replace a comprehensive and informed approach to prevention.
Source: AllAfrica — read the original report.
